title: The effects of NSAIDs on types I, II, and III collagen metabolism in a rat osteoarthritis model.
abstract: The effects of long-term use of celecoxib, ibuprofen, and indomethacin on types I, II, and III collagen metabolism were evaluated in rat osteoarthritis (OA) model. One hundred and thirty wistar rats were randomly divided into 4 groups: the celecoxib group, the ibuprofen group, the indomethacin group, and the normal saline group. The osteoarthritis was induced by the excision of the left Achilles tendon. In the 3rd, 6th, and 9th month of treatment after surgically induced osteoarthritis, the articular cartilage was observed with microscope using HE staining. The expression of proteoglycans was semiquantified using toluidine blue staining. And, the expressions of types I, II, and III collagen in chondrocytes were examined using immunohistochemistry. The results suggested that celecoxib had no remarkable effects on the expression of types I, II, and III collagen. Ibuprofen upgraded the expression of types I, II, and III collagen and increased the synthesis of collagen. Indomethacin suppressed the expression of type II collagen and enhanced the expression of types I and III collagen. Therefore, during the long-term use of NSAIDs in osteoarthritis, celecoxib may have no remarkable influences on collagen metabolism of the articular cartilage and may be the ideal choice in the treatment of chronic destructive joint disease when anti-inflammatory drugs need to be used for a prolonged period. Ibuprofen may be unfavorable, and indomethacin may be harmful to collagen metabolism in OA treatment.
authors.affiliation: Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
authors.forename: Yun-Sheng
authors.initials: YS
authors.lastname: Ou
authors.forename: Chao
authors.initials: C
authors.lastname: Tan
authors.forename: Hong
authors.initials: H
authors.lastname: An
authors.forename: Dian-Ming
authors.initials: DM
authors.lastname: Jiang
authors.forename: Zheng-Xue
authors.initials: ZX
authors.lastname: Quan
authors.forename: Ke
authors.initials: K
authors.lastname: Tang
authors.forename: Xiao-Ji
authors.initials: XJ
authors.lastname: Luo
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002358:Cartilage, Articular / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D000068579:Celecoxib; D019902:Chondrocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D024042:Collagen Type I / Q000378:metabolism*; D024043:Collagen Type II / Q000378:metabolism*; D024061:Collagen Type III / Q000378:metabolism*; D004195:Disease Models, Animal; D007052:Ibuprofen / Q000494:pharmacology; D007150:Immunohistochemistry; D007213:Indomethacin / Q000494:pharmacology; D010003:Osteoarthritis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011509:Proteoglycans / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides / Q000494:pharmacology; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D024042:Collagen Type I; D024043:Collagen Type II; D024061:Collagen Type III; D011509:Proteoglycans; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; D007052:Ibuprofen; D007213:Indomethacin